Non-alcoholic fatty liver disease future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parth Vikram Singh, MBBS

Please help WikiDoc by adding content here. It’s easy! Click here to learn about editing.

Future investigational therapies for MASH include tirzepatide and other dual- or triple-incretin receptor agonists, gliflozins, pan-peroxisome proliferator-activated receptor agonists such as lanifibranor, fibroblast growth factor 21 analogs, fatty acid synthase inhibitors, and genetic target-based therapies such as antisense oligonucleotides targeting PNPLA3.^[1]

Blood-based biomarkers of fibrosis and vibration-controlled transient elastography are expected to be used more frequently to monitor disease progression and regression, predict long-term liver-related events, and assess treatment response. Polygenic risk scores, metabolic signatures, and microbiome signatures may help identify patients with distinct MASLD trajectories and treatment responses.

Template:WS Template:WH